While, we had initially hoped that expression of TYK2 could serve as a potential biomarker distinguishing MPNSTs from other soft tissue sarcomas, we observed high expression in 38%‐89% of other sarcomas as well. This evidence concerns the gene TYK2 and soft tissue sarcoma.